References
- Pemble S, Schroader KR, Spencer SR et al. Human glutathione S-transferase theta (GSTT I): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994; 300: 271–276.
- Maeda Y, Sumimoto Y, Nawata H, Matsuda M, Kanamaru A. Deleted mutation of GSTT-1 gene in patients with MDS. Leukemia 1998; 12: 2039.
- Maeda Y, Yamaguchi T, Ueda S et al. Mutant type glutathione S-transferase theta 1 gene homologue to mTOR in myelodysplastic syndrome:possible clinical application of rapamycin. Leukemia Lymphoma 2003; 44: 1179–1185.
- Sabers CJ, Martin MM, Brunn GJ et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270: 815–822.
- Brown EJ, Albers MW, Shin TB et al. A mammalian protein targeted by GI -arresting rapamycin-receptor complex. Nature 1994; 369: 756–758.
- Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78: 35–43.
- Chiu MI, Katz H, Berlin V et al. RAPT1, a mammalian homologof yeast TOR, interacts with the FKBPI2/rapamycin complex. Proc Nall Acad Sci USA 1994; 91: 12574–12578.
- Dumont FJ, Su Q. Mechanism of action of the immunosuppres-sant rapamycin. Life Sci 1996; 58: 373–395.
- Sehgal SN, Molnar-Kimber K, Ocain TD, Weichman BM. Rapamycin: a novel immunosuppressive macrolide. Med Res Rev 1994; 14: 1–22.
- Dilling MB, Dias P, Shapiro DN, German GS, Johnson RK, Houghton Pi. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibitor of signaling via the type I insulin-like growth factors receptor. Cancer Res 1994; 54: 903–907.
- Hosoi H, Dilling MB, Liu N et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998; 54: 815–824.
- Calestretti A, Racati F, Ceriani MC, Asnaghi L, Canti G, Nicolin A. Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. Eur J Cancer 2001; 37: 2121–2128.
- Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19: 6680–6686.
- Dudkin L, Dilling MB, Cheshire PJ et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor inhibition. Clin Cancer Res 2001; 7: 1758–1764.
- Geoerger B, Kerr K, Tan CB et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma model as single agent in combination chemotherapy. Cancer Res 2001; 61: 1527–1532.
- Huang S, Shu L, Easton J et al. Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem 2004; 279: 36490–36496.
- Ly C, Arechiga AF, Melo TV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003; 63: 5716–5722.
- Harding MW. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res 2003; 9: 2882–2886.
- Gao N, Zhang Z, Jiang BH, Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 2003; 310: 1124–1132.
- Mita MM, Mita A, Rowinsky EK. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 2003; 4: 126–137.
- Recher C, Beyne-Rauzy O, Demur C et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105: 2527–2534.
- Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995; 55: 1982–1988.
- Yamamoto-Yamaguchi Y, Okabe-Kado J, Kasukabe T, Honma Y. Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors. Exp Hematol 2001; 29: 582–588.
- Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003; 63: 5716–5722.
- Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102: 972–980.
- Platzbecker U, Haase M, Herbst R et al. Activity of sirolimus in patients with myelodysplastic syndrome—results of a pilot study. Br J Haematol 2005; 128: 625–630.